More Success in PsA for IL-17 Blocker

]]>(MedPage Today) -- At the recent 2019 American College of Rheumatology meeting in Atlanta, a study was presented showing ixekizumab (Taltz) to be superior to placebo for treating patients with active psoriatic arthritis and previous inadequate...